An emerging group of high-grade renal cell carcinomas (RCCs), particularly carcinomas arising in the hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC), show fumarate hydratase (FH) gene mutation and loss of function. On the basis of similar cytomorphology and clinicopathologic features between these tumors and cases described as tubulocystic carcinomas with poorly differentiated foci (TC-PD) of infiltrative adenocarcinoma, we hypothesized a relationship be-tween these entities. First, 29 RCCs with morphology of TC-PD were identified retrospectively and assessed for FH expression and aberrant succination (2SC) by immunohistochemistry (IHC), with targeted next-generation sequencing of 409 genesincluding FH-performed on a subset. The 29 TC-PD RCCs included 21 males and 8 females, aged 16 to 86 years (median, 46), with tumors measuring 3 to 21 cm (median, 9) arising in the right (n = 16) and left (n = 13) kidneys. Family history or stigmata of HLRCC were identifiable only retrospectively in 3 (12%). These tumors were aggressive, with 79% showing perinephric extension, nodal involvement in 41%, and metastasis in 86%. Of these, 16 (55%) demonstrated loss of FH by IHC (14/ 14 with positive 2SC). In contrast, 5 (17%) showed a wild-type immunoprofile of FH+/2SC À. An intriguing group of 8 (28%) showed variable FH ± positivity, but with strong/diffuse 2SC+. Next-generation sequencing revealed 8 cases with FH mutations, including 5 FHÀ /2SC+ and 3 FH ± /2SC+ cases, but none in FH+/2SC À cases. Secondly, we retrospectively reviewed the morphology of 2 well-characterized cohorts of RCCs with FH-deficiency determined by IHC or sequencing (n = 23 and n = 9), unselected for TC-PD pattern, identifying the TC-PD morphology in 10 (31%). We conclude that RCCs with TC-PD morphology are enriched for FH deficiency, and we recommend additional workup, including referral to genetic counseling, for prospective cases. In addition, based on these and other observations, we propose the term "FH-deficient RCC" as a provisional term for tumors with a combination of suggestive morphology and immunophenotype but where genetic confirmation is unavailable upon diagnosis. This term will serve as a provisional nomenclature that will enable triage of individual cases for genetic counseling and testing, while designating these cases for prospective studies of their relationship to HLRCC.
T ubulocystic carcinoma of the kidney was likely first recognized as the "Bellinien epithelioma" or collecting duct carcinoma by Pierre Masson in the 1950s and as "low-grade collecting duct carcinoma" in the third series AFIP fascicle. 1 On the basis of the experience with a cohort of such cases and observation of their distinctive morphology and relatively favorable prognosis, in 2004 some of us proposed "tubulocystic carcinoma of the kidney" as a separate class of renal cell carcinoma (RCC), reporting 31 cases in 2009. 2 Tubulocystic carcinoma was formally included as a distinct entity in the International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia 3 
and the recent 4th
Edition World Health Organization Classification of kidney tumors. 4 Tumors present grossly as a complex cystic mass characteristically in male patients (M:F ratio of B7:1) during their seventh decade. These tumors demonstrate a consistent morphology of variably cystically dilated tubules, admixed with a background of fibrous stroma, and lined by markedly atypical cells with eosinophilic cytoplasm and high-grade nuclei with prominent nucleoli (ISUP nucleolar grade 3). Belied by their high-grade nuclear features, most reported tumors have been low stage with only rare reports of clinical progression and aggressive behavior. 2, [5] [6] [7] [8] [9] Recently, 3 cases of RCC with the morphologic pattern of tubulocystic carcinoma, with concomitant areas of a high grade, infiltrative adenocarcinoma remi-niscent of collecting duct carcinoma, were reported by 2 of the current authors and termed "tubulocystic carcinoma with poorly differentiated foci" (TC-PD). 10 In each of these cases, there was an extensive, classic tubulocystic carcinoma-like morphology, involving between 30% and 90% of the tumors. However, other morphologic patterns were present, with 2 of 3 showing at least focal papillary morphology and all 3 demonstrating variable proportions of infiltrative high-grade tubular adenocarcinoma with collecting duct-type features, invading perinephric adipose in 2. A very recent report provides 2 further examples of such cases, emphasizing their aggression, 11 and illustrative of the wisdom of the Vancouver Classification's recommendation not to designate tumors with such a mixed features as tubulocystic carcinoma. 3 In recent years, we have increasingly recognized in our consultation and hospital-based practices a number of cases showing this morphologic pattern. Although we have diagnosed these cases as RCC, unclassified, per contemporary recommendations, providing additional descriptive commentary about the morphology, some of our cases demonstrated intriguing high-grade nuclear features. In particular, we believed that we were observing nucleolar forms reminiscent of the prominent, viral inclusion-like nucleolus with perinucleolar halo described previously as the cytomorphologic hallmark of RCCs arising in the setting of hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC-RCCs). 12 HLRCC syndrome is caused by germline mutation of fumarate hydratase (FH), resulting in a highly penetrant (>90%) uterine and cutaneous leiomyomatosis with variably penetrant (estimated 5% to 20%) high-grade RCC with papillary or collecting duct-like morphology. 13 More recently an expanded histologic spectrum of HLRCC-RCC has been described, 12 and some of us have even reported cases where areas resembling tubulocystic carcinoma were admixed with tubulopapillary and papillary patterns. 14 Importantly, HLRCC-RCCs are exceptionally aggressive tumors, often presenting at high stage, underscoring the importance of their recognition. 12, 14 Thus, recent reports propose immunohistochemical (IHC) adjuncts for screening for HLRCC-RCCs, including staining for FH protein expression, which may be lost in a majority of cases [15] [16] [17] [18] and for aberrant succination of nuclear and cytoplasmic proteins (S-(2-succino)-cysteine, 2SC), which is induced upon loss of FH function. 14, 17, 19, 20 The suggestive overlapping nuclear findings between many of our index TC-PD cases and HLRCC-RCCs led us to study this entity in greater detail, with an eye to clarifying the nosologic and molecular relationships between these tumors. This, we undertook via complementary studies of cases selected for TC-PD morphology on one hand, and by retrospective morphologic review among bona fide FH-deficient carcinomas, searching for TC-PD morphology, on the other. Significantly, we identified a group of tumors within the aforementioned morphologic spectrum but lacking family history or syndromal evidence of HLRCC despite FH deficiency. Since there is no appropriate terminology to designate tumors (whether showing TC-PD or the other reported patterns) demonstrating this immunophenotype in the contemporary classification schema for RCC, 3 we have proposed the term FH-deficient RCC 21 for provisional use, pending definitive workup for germline FH mutation.
METHODS

Cases and Cohorts
This study is a retrospective clinicopathologic, morphologic, IHC, and molecular review of cases of TC-PD. The first cohort is composed of cases identified, based on TC-PD morphology alone, retrospectively from pathology database searches of the contributing institutions and upon review of cases of high-grade distal nephron adenocarcinomas assembled in an international collaborative effort, approved by the Institutional Review Boards of contributing institutions. Medical and surgical pathologic records were reviewed to tabulate deidentified demographic and clinicopathologic data. The criterion used for TC-PD cases was defined morphologically as tumor with at least some component of classic tubulocystic carcinoma with adjacent or admixed high grade, infiltrative, tubular/tubulopapillary, solid, or cribriform adenocarcinoma. Classic tubulocystic carcinoma morphology was defined as previously reported 2 and described above. All cases were reviewed by multiple authors (S.C.S.
The second cohort of cases studied is composed of 2 published, well characterized cohorts of cases with FHdeficient status (n = 23) 18 or HLRCC-RCC (n = 9). 14 These previously reported cases were reviewed to determine whether any TC-PD morphology were apparent, at least focally. For cases where TC-PD morphology was identified upon this review, updated clinical, morphologic (as described below), and molecular data were tabulated (by K.T./A.J.G. and Y.-B.C./S.K.T./V.E.R., respectively).
Review of Gross and Microscopic Tumor Morphology
For the first cohort, using gross description and photographs available for a subset of cases, pathologic parameters including size, focality, and location within the kidney (medullary vs. cortical), were tabulated, as was the gross impression of the tumor, whether circumscribed and/or infiltrative, whether or not it was cystic, and whether necrosis was grossly evident. The presence of a number of microscopic architectural patterns was evaluated. These included patterns of (1) infiltrative adenocarcinoma with desmoplastic stroma (collecting duct carcinoma-like); (2) multinodular infiltrative papillary pattern (variably sized invasive papillary nodules with intervening desmoplastic reaction; (3) tubular, tubulopapillary, and papillary pattern; (4) nonglandular pattern, including solid sheets, cords, variably sized nests, and rhabdoid areas; (5) intracystic papillary growth; (6) cribriform morphology; (7) conventional tubulocystic carcinoma-like morphology; and (8) yolk sac carcinomalike pattern with reticular architecture. These patterns were considered for each case, and quantitated as primary if involving Z50% of the tumor, secondary, if involving a substantial but lesser component of the morphology (10% to 49%), or focal (r10%). Presence or absence of coagulative tumor cell necrosis was evaluated for each case, as was the nucleolar grade, both as defined by the ISUP Vancouver recommendations for prognostic parameters. 22 Finally, the specific nuclear feature of a large nucleus with very prominent inclusion-like orangiophilic or eosinophilic nucleolus with perinucleolar halo (virallike inclusion) was additionally scored for each case, including if present focally (r10% cells) or diffusely.
Again, for the first cohort of new cases, IHC for FH was performed by use of clone J-13, Santa Cruz Biotechnology, essentially as reported previously, 19, 20 but at dilution of 1:1000 or at 1:100 under CLIA-validated IHC testing protocols performed by 2 of our IHC laboratories (a subset of our cases were studied by both with identical results). Our 2SC staining protocol has been reported previously. 14 The FH staining was visually scored qualitatively as negative or positive when compared with internal positive control (endothelial cells), excepting a subset of cases showing weak, variable FH staining that was at least focally positive, which were designated FH ± . The 2SC staining assessed for intensity (1+ to 3+) and staining pattern (nuclear and cytoplasmic vs. cytoplasmic only), although only 3+ intensity nucleocytoplasmic staining was interpreted as positive, also as reported previously. 14 Reflective of experience of ours 14, 20, 21 and others [15] [16] [17] 19 with relation of FH and 2SC immunophenotype to FH mutational status, we classified the immunophenotypes observed as FH+2SC À as "FHretained," FH À 2SC+ as "FH-deficient," and FH ± 2 SC+ as "FH-suspicious."
Molecular Studies
Tumors from the first cohort identified based on TC-PD morphology where archival materials were available were also studied via multiplexed PCR-based next-generation sequencing (NGS), with IRB approval, using the Ion Torrent Comprehensive Cancer Panel as we have reported previously. [23] [24] [25] First, if technically possible based on available archival material, conventional tubulocystic carcinoma-like areas and poorly differentiated areas were carefully separately macrodissected after review of paired H&E slides (S.A.T.). In cases where these morphologies could not be separated, tumor was carefully macrodissected from normal tissues, and the percentage of tumor content estimated. Four cases of conventional TC-PD areas were also analyzed for comparison. Briefly, NGS was performed on isolated DNA from each sample using the Comprehensive Cancer Panel, which targets B16k amplicons including the complete coding sequence of 409 cancer-related genes. Libraries were created using the Ion Ampliseq Library Kit 2.0 and barcoded for multiplex analysis, with templates prepared using the Ion PI Template OT2 200 Kit version 3 on the Ion One Touch 2, with sequencing on the Ion Torrent Proton Sequencer using P1 chips and the Ion PI Sequencing 200 Kit version 3. Data analysis was performed exactly as described, 25 using Torrent Suite (4.2.0), the Coverage Analysis Plug-in (v4.0-r73765), and in-house validated annotation, filtering, and prioritization pipelines to identify high confidence, prioritized somatic mutations, with the exception of requiring called variants to have variant allele frequencies (FAO/FDP) > 10% and all FH variants were prioritized if otherwise meeting our usual criteria. To identify copy number alterations, normalized, GC-content-corrected, total read counts per amplicon for each sample were divided by those from a composite normal sample yielding a copy number ratio for each amplicon. Gene-level copy number estimates were determined by taking the coverage-weighted mean of the per-probe ratios, with expected error determined by the probe-toprobe variance, as we have reported previously. [23] [24] [25] [26] 
RESULTS
Clinical and Gross Features of TC-PD
TC-PD morphology was studied by complementary approaches in 2 cohorts. The first was by retrospective review of cases identified in database searches for TC-PD morphology among cases encountered in the surgical pathology practices of the authors and contributed in an international collaborative consortium studying highgrade adenocarcinomas arising in the distal nephron (high-grade distal nephron adenocarcinoma) (n = 29). These cases arose in 21 males and 8 females, for an overall M:F ratio of 2.6. The patients included 14 (48%) of white, 2 (7%) of Asian, and 5 (17%) of reported African descent (no data for 8, 28%). Ages ranged from 16 to 86 years, with a median age of 46 years. The tumors were unilateral in all cases, arising in the right kidney (n = 16) and left kidney (n = 13) (Figs. 1A, B). No case had personal or family history of HLRCC, nor any clinical consideration of such, in any available medical records. Three cases, however, had findings, identified retrospectively upon review of the kidney tumors, compatible with or suggestive of an association with HLRCC. Case 4 had a firstdegree relative with metastatic RCC, respectively, whereas case 13 had a first-degree relative with multiple cutaneous leiomyomas. Case 7 had no family history but had numerous uterine leiomyomas described radiologically as a "remarkably myomatous uterus."
Grossly, the tumors ranged in greatest dimension from 3 to 21 cm, with a median of 9 cm. Among cases where the growth pattern of the tumor was described grossly (n = 26), these were described equally as circumscribed (50%) or infiltrative/poorly defined (50%), with a subset (23%) including additional description of a cystic or multicystic gross appearance (Figs. 1C, D). Of 27 cases where the gross pattern of involvement was detailed by anatomic compartment of the kidney, 26% were predominantly cortically based, 19% were predominantly medullary based, and 56% involved both, often diffusely.
From the standpoint of staging, correlating gross and microscopic impressions in 28 cases, only a subset were confined to the kidney (21%, stages pT1-2), whereas 79% were pT3a-4, including gross and/or microscopic invasion of the renal vein in 9 of 27 cases (33%). Lymph nodes were sampled in 22 cases and were involved by carcinoma in 9 (41%). At presentation, metastasis was apparent in 9 cases, while it was observed during follow-up in an additional 10 cases over a median 9 months of available follow-up (total 19/22 cases with available data), including frequent liver, lung, and bone metastasis (in 52%, 52%, and 42% of cases with metastasis, respectively). Table 1 summarizes the clinical features of these cases.
Microscopic Features of TC-PD
Microscopically, these cases demonstrated variable components of morphology as described for tubulocystic carcinoma of kidney in all cases. In 11 cases (38%), tubulocystic areas represented the predominant pattern and involved over half of the tumor; in 10 cases (34%) tubulocystic morphology was a significant but secondary morphology (10% to 49% of the tumor); in 8 cases (28%) it was focal. Figures 2A-D presents 4 cases, showing a representative range of tubulocystic versus poorly differentiated morphology at low power. Overall, after tubulocystic morphology (primary or secondary pattern in 72% of cases), the most common predominant patterns presented included tubular or tubulopapillary pattern (21%) and nonglandular pattern (solid/sheet-like, nested, cord-like, rhabdoid, 17%). Less frequent were patterns of multinodular infiltrative papillary and infiltrative tubular adenocarcinoma with desmoplasia (collecting duct carcinoma-like) patterns predominant in 2 cases each (each 7%).
Variable nontubulocystic morphologies were present. Patterns present more than focally (>10%), in order of prevalence, included tubular/tubulopapillary morphology (48%), nonglandular sheets, nests, or cords (41%), cribriform growth (28%), infiltrative adenocarcinoma with desmoplasia (17%), intracystic papillary growth (14%), and multinodular infiltrative papillary (10% between these 3 groups, we observed significantly different distributions (P = 0.003 Kruskal-Wallis), such that the FH-suspicious and FH-deficient cases had significantly lower median ages (each 45 y) than the FH-retained cases (74 y), whereas laterality (P = 0.5 w 2 ), tumor size (P = 0.4, Kruskal-Wallis), and proportion of tubulocystic morphology (P = 0.06, w 2 ) did not differ significantly in distribution by immunophenotypic group. The only significantly different morphologic feature was that a higher proportion of FH-retained cases demonstrated focal rather than diffuse presence of inclusion-like nucleoli with perinucleolar halos (4/5) than did FHsuspicious (3/8) or FH-deficient (3/16) (P = 0.04), acknowledging the cohort size. Nodal status (P = 0.34) and metastatic progression (P = 0.98) did not differ between groups.
Molecular Analysis of TC-PD
To assess for coding mutations and copy number alterations in 409 cancer-related genes, including FH, we performed multiplexed PCR Ampliseq-based NGS on a total of 20 tumor samples. These constituted 16 samples from 11 TC-PD cases, which included 5 cases where paired tubulocystic and poorly differentiated components could be dissected and analyzed separately for comparison, and 6 cases where intimately admixed tubulocystic and poorly differentiated areas could not be separately analyzed. Four additional "conventional" tubulocystic carcinomas were also studied. Considering all rare FH variants (whether deleterious or not) and all highconfidence prioritized nonsynonymous variants identified by our validated analysis pipelines, 23, 24, 26 we identified a total of 8 cases with FH alterations, including focal copy number deletion, and missense and frameshift mutations. In all cases where paired tubulocystic and poorly differentiated components could be separately dissected and analyzed, the same mutations were identified at comparable variant allele frequencies in both components. The 5 cases showing the FHÀ /2SC+, FH-deficient immunophenotype that were assessed by NGS demonstrated zProgression: time to first metastatic progression, months; P, metastatic at presentation; -, no data. #Status: last available status at follow-up; DOD, dead of disease; NED, no evidence of disease; LTF, lost to follow-up; AWD, alive with disease; DNOS, dead, not otherwise specified; -, no data. the following FH mutations: 1 case with focal, high-level 2copy deletion of the FH gene (spanning all FH amplicons, Fig. 6A ), 1 K230R homozygous mutation, 1 R101X homozygous mutation, and 2 cases with homozygous frameshifts, 1 at K80 and 1 at Y251. Among 4 cases analyzed that showed the FHsuspicious immunophenotype, FH ± /2SC+, we observed FH mutations in 3; 1 case showed heterozygous N188T and H318Y mutations, another case harbored a V279F homozygous mutations, and a third case harbored a R233H homozygous mutation. The latter R233H case also demonstrated a second prioritized, high-confidence somatic CREBBP R1341X mutation (heterozygous). On the basis of the documentation of the FH mutations, we reclassified these FH-suspicious cases as FH-deficient RCC (see cases TC-PD 17-19, cases numbered as per Tables 1, 2 ). The fourth FH ± /2SC+ case analyzed demonstrated a "hypermutator" phenotype, exhibiting thousands of mutations, including nonspecifically, mutations of FH. All identified FH mutations are shown in relation to the exon structure of FH in Figure 6B .
Two cases of TC-PD that showed a FH-retained FH+/2SC À immunophenotype were among those studied by NGS. Neither case harbored FH mutations. One case showed no prioritized variants in any of the 409 genes studied; the other case demonstrated a prioritized 2bp frameshifting deletion at residue 832 of ARID1A. Four cases of "conventional" tubulocystic carcinoma were also studied by NGS; none showed FH mutations. Two of these did not show any prioritized nonsynonymous variants among all genes studied, while one showed a 7bp deletion at codon 4509 of KMT2C and one other showed a 16bp deletion at codon 888 of KDM5C and a R337H mutation of TP53. Table 2 summarizes the immunophenotypic and sequencing findings for each of these TC-PD cases. now all known to harbor FH mutations as above) versus FH-retained TC-PD and conventional tubulocystic carcinomas, with the exception of 1 case, TC-PD 3. Secondary branching of the dendrogram revealed 4 groups, 1 cluster containing the 4 conventional tubulocystic carcinomas, and paired low and high-grade components from an FH-retained TC-PD 28. These tumors were characterized by chromosome 9 losses and gains of chromosomes 17 and 16, with chromosome 16 gains observed only in the conventional tubulocystic carcinomas. A second cluster comprised of low and high-grade components from 2 TC-PDs (1 each with and without retained FH), also showed gains of chromosome 16 and 17, but also harbored gains of chromosome 7. The other 2 clusters, consisting entirely of FH-deficient or FH-suspicious TC-PD, lacked the above alterations and showed more variable alterations, most frequently losses of chromosome 18 and gain of chromosome 8q. Focal, high-level gains or losses were rare in our cohort, but included FH deletions in the paired components of TC-PD 7 (described above), a focal 2 copy 6p loss (encompassing EPHA7 and MAP3K7) in both the low and high-grade components of TC-PD 3 (FH-deficient), and a focal 2 copy loss of CDKN2A exclusively in the high-grade component of TC-PD 27 (FH-retained).
TC-PD Morphology Identified Retrospectively Among Tumors With FH Deficiency
Lastly, we used the reverse experimental design to study the relationship between TC-PD morphology and FH-deficient RCC in a second cohort composed of 2 previously reported series of RCCs with FH-deficiency (n = 23, and n = 9), 14, 18 reasoning that if TC-PD morphology were associated with FH-deficiency, then the pattern of TC-PD areas might be recognized retrospectively. Among the 23 cases of FH-deficient RCC reported by Trpkov and colleagues, TC-PD morphology was seen in 7 (30%), while of the 9 cases of HLRCC reported by Chen and colleagues TC-PD was apparent in 3 (33% TC-PD 1  18  M  FH-D  1, 3  -1  2  0  0  4  Lost  --TC-PD 2  20  M  FH-D  2  C,M  1  2  1  0  3 &FH Mutation: homozygous for the indicated mutation; if heterozygous mutant, both listed; otherwise as indicated; -, no data. 
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Genome-wide CNAs -Case TC-PD 7
Clustering Cases by Genome-wide CNAs Reported Mutations FIGURE 6. Molecular findings in TC-PD by NGS. A, Focal, high level gains or losses were rare in our cohort, but included 1 case, TC-PD 7, which showed a focal homozygous FH deletion on chromosome 1 (inset), present in both the tubulocystic and poorly differentiated areas. B, Mutations identified in FH in TC-PD cases were well within the spectrum of that described previously for FH; here MutationMapper (cBioPortal 27 ) was used to plot all previously reported unique FH mutations from the FH mutation database 28 (purple, green, and red, as indicated), whereas mutations reported herein are indicated in blue. All mutations we identified were in the lyase domain (green). C, Hierarchical clustering based on inferred genome-wide copy number was performed for indicated TC-PD samples (shades of green and blue, indicated, with pairing indicated by black, white, or gray) and conventional tubulocystic carcinomas (purple), identified 2 main branches in the dendrogram, correlating mostly with IHC type (shades of brown). Conventional tubulocystic carcinomas clustered in a subcluster with 1 FH-retained TC-PD.
Content 4, http://links.lww.com/PAS/A411) presents these cases with updated clinical, morphologic, and molecular features.
DISCUSSION
The association of multiple cutaneous and uterine leiomyomas was first reported by Reed et al. 29 Subsequently, building on findings of a group of such families also affected by an aggressive RCC, the association of this type of RCC with multiple cutaneous and uterine leiomyoma was reported in 2001, renamed HLRCC, 30 and mapped to a locus on the long arm of chromosome 1 shown to be the locus of FH. 31 HLRCC demonstrates among affected males and females a highly penetrant (75% to 100%, average onset at 25 y) phenotype of multiple painful cutaneous leiomyomas, particularly on the face, torso, and extremities. Among affected females multiple uterine leiomyomas are also highly penetrant, often requiring surgery at a young age, reviewed recently. 13, 32 Adrenocortical adenomas have been reported in B10%. 13, 33 Classic reports of the morphology of the less penetrant (< 5% to 20%, depending on the series 13, 34 ) RCCs that arise in these patients described them as "type 2 papillary" or collecting duct carcinoma-like RCCs, though their wider morphologic spectrum, including papillary, tubulopapillary, tubular, and solid examples, and distinctive cytologic features, including large viral inclusion-like nucleolus with perinucleolar halo were first detailed in a series by Merino et al. 12 Although the morphology, tumor size, and age of onset observed varied greatly, most important was the clinicopathologic observation of a ubiquitously aggressive course, with frequent metastasis and high-stage presentation. Recent reports emphasize the potential to use IHC for FH itself or 2SC (biochemical consequence of FH dysfunction) for identification of such cases. 14, 17, 18, 20 We believe that our experience reported herein, further characterizing RCC cases which we have descriptively labeled as TC-PD (as reported previously 10 ), lends novel understanding regarding their aggressive behavior by identifying FH-deficient immunophenotype (and/or FH mutations detected among tumors) among a significant subset. Also, for at least the subset of FHdeficient cases, our findings argue against the potential relationship with conventional papillary RCC postulated in the original description of TC-PD. 10 Noting the cytomorphologic hallmark described in HLRCC-RCCsprominent inclusion-like nucleoli and perinucleolar halo 12 -in several cases encountered in our practice, we retrospectively identified a cohort of TC-PD, using contemporary FH and 2SC IHC to characterize the immunophenotype. Our findings suggest that well over half of these cases represent FH-deficient tumors, demonstrating the FH À /2SC+ immunophenotype and FH mutations in all such cases tested. This central finding is further supported by the observation of cases with TC-PD morphology identified from 2, independent, previously reported cohorts of RCCs with FH deficiency (by IHC and/or molecular studies) that were identified from among high-grade unclassified RCCs and unclassified RCCs with papillary features. 14, 18 We interpret these findings as strong support for the premise that the TC-PD pattern, observed presenting sporadically by not only us but also by at least 2 other groups, 10, 11 represents in most cases a morphologic variation of RCC with FH deficiency.
We posit that when encountered prospectively, RCCs with TC-PD morphology, at the very minimum, deserve recommendation of additional workup with consideration first of FH-deficient status, and then, if identified, for HLRCC with referral for genetic counseling. This observation regarding TC-PD pattern is also consistent with prior descriptions of the morphologic range of cases reported with FH-deficiency. While the morphologic tour de force provided by Merino et al 12 in their report of 40 tumors did not use the term "tubulocystic" to describe HLRCC-RCC cases (indeed "tubulocystic carcinoma of the kidney" had barely been reported before this study) we do note that they reported 21/40 cases with at least a minor cystic component. Another very recent report also identifies 1 example of an RCC with predominant tubulocystic pattern, with FH mutation, 35 again, very consistent with our observations. It is tempting also to consider our TC-PD finding in light of prior findings from a mouse model, using a kidneyspecific biallelic FH knockout strategy, which observed onset of clonal, proliferative cysts thought to arise from the collecting ducts and thick ascending limb of the loop of Henle. 36 Indeed, a recent case report of an HLRCC patient seems to describe an apparently benign multicystic lesion the kidney contralateral to an HLRCC-RCC, contemplating a precursor lesion. 37 Much less clarity, then, regards the relationship of our FH-deficient TC-PD cases to syndromal HLRCC. Overall the lower median age seen among the FHdeficient carcinomas and suspicious FH ± 2SC+, is at least consistent with consideration of a component of syndromal neoplasia. Remarkably, nonetheless, in the cohort of 29 TC-PDs, only 3 cases demonstrated any clinical evidence suggestive of or compatible with HLRCC, elicited only retrospectively, including 1 with family history of multiple cutaneous leiomyomas, 1 with family history of RCC, and 1 with concurrent, extensive uterine leiomyomas. The mutations that we observed in the subset of FH-deficient cases studied are entirely within the spectrum of germline mutations seen in HLRCC, including some involving residues reported as mutated in HLRCC previously, while others are as yet unreported. We note with regards to the novel variants observed that the argument has been made that most missense mutations of FH are likely pathogenic, given the high degree of conservation of the protein across taxa. 28 We also emphasize that these were detected from mutational profiling of tumors rather than the germline, which is the "gold standard" for diagnosis of this syndrome.
We do note that some of our prior experience supports the idea that HLRCC-RCC cases may present apparently sporadically, yet in fact represent bona fide germline HLRCC. 14 Similarly, other investigators have recently found that a renal tumor may be the first and only manifestation of HLRCC (with germline FH gene mutation). 38 We also acknowledge that the penetrance of uterocutaneous leiomyomatosis and RCC in HLRCC might be even more variable across different geographic or ethnic groups than in those reported previously. 13 However, we would also highlight emerging data with regards to purely somatic FH mutations. Somatic FH mutation was previously considered to be quite rare, at least among uterine leiomyomas, 13, 39, 40 but emerging data with contemporary sequencing technologies suggest this may not be quite so. Indeed, a very recent cohort identified FH mutations in B1% of leiomyomas presenting sporadically, among a testable subset of which all were confirmed not to be germline. 41 In tandem, and more a propos to RCC, are the data from the recently reported TCGA cohort of papillary RCCs, identifying a CpG island methylator phenotype (a molecular hallmark consistent with FH deficiency) in 9/60 "type 2" papillary RCCs, among which 5 tumors showed "germline or somatic mutation of FH" and among all of which were noted "decreased expression of FH mRNA". 42 In light of these emerging findings, we are even more suspicious that somatic mutation of FH (or other mechanisms) might represent a way to attain the FH-deficient phenotype; indeed, one of our cases showing patchy loss of FH (FH ± /2SC+) and showing an unusual hypermutator molecular phenotype characterized by innumerable mutations of all genes studied (including FH, though such might represent an epiphenomenon) would seem to be at least one example thereof. In this particular case, the mutator phenotype was in some ways similar to that seen in neoplasms with dysfunctional mismatch repair such as arise in Lynch Syndrome, although MLH1, MSH2, MLH6, and PMS2 expression were all retained by IHC, data not shown. This latter case raises the issue of tumors with the immunophenotype of FH ± /2SC+, which some of us have designated as "equivocal" or "indeterminate" in prior reports. 18 Our experience with these cases, which include 25% of the present cohort, leads us to be quite suspicious and designate cases with this immunophenotype and appropriate cytomorphology as suspicious for FH-deficient RCC; indeed, 3 of the 4 FH ± / 2SC+ cases studied by NGS exhibited FH mutations, presumably that result in retained expression of a dysfunctional or hypomorphic allele. Of these H318Y and R233H have been reported previously; N188T is novel, although the closely related N188S variant has been reported; V279F is novel but adjacent to residues previously reported mutated. 28 Prior experience with FH versus 2SC immunostain suggests that the 2 perform similarly, perhaps 2SC with greater sensitivity but less specificity. For example, some of us have reported in abstract form that of 14 genetically confirmed HLRCC-RCC cases, 12 (86%) exhibited loss of FH expression while all 14 showed induction of nucleocytoplasmic 2SC expression. 20 Importantly, some of us have reported previously that cytoplasmic (but not nucleocytoplasmic) 2SC positivity may be seen in high-grade unclassified and papillary RCCs, 14 which might be prospectively difficult to interpret. Overall, our assessment is that use of both markers would be ideal, emphasizing the caveats that retained FH staining does not exclude mutation resulting in expression of a dysfunctional protein and that the full spectrum of 2SC positivity remains unclear. Notably, even many targeted sequencing protocols currently in use would not detect the FH deletions reported in a subset of HLRCCs. Certainly, we emphasize that at present 2SC is only available in a research setting, while FH, for which a monoclonal antibody exists, is becoming increasingly available in CLIA-compliant laboratories. Either way, we recommend inclusion of commentary suggesting genetic counseling and germline sequencing in any cases where morphologic, immunophenotypic, or clinical settings are unclear.
Lastly, we observed a subset of FH+/2SC À cases that show a "wild-type" immunophenotype with respect to FH status. Our observation that there exists a distinct subset of cases with no molecular or immunophenotypic evidence implicating dysfunction in FH or HLRCC suggests that this morphology can occur due to lesions in or alterations in other cellular pathways. Indeed, at least among one of the FH+/2SC À TC-PD cases, we observed mutation of an FH-unrelated gene, ARID1A, known to be significantly mutated in ovarian clear cell carcinoma (B50%) and gastric adenocarcinoma (B30%), 43 and among a frequently mutated SWI/SNF gene cluster in clear cell RCC 44 and urothelial carcinoma (mutated in B25%). 45 In summary, we find that the TC-PD morphologic pattern in RCC is strongly associated with FH-deficient status. Importantly, from the standpoint of prospective practice in surgical pathology, these cases most often are not encountered with clinical evidence of HLRCC family history or stigmata, even on close questioning and examination. Despite this fact, genetic counseling to rule out germline mutation should be recommended, as it is likely that a significant proportion will be associated with germline FH mutation. In any case, the remarkable aggressiveness of disease seen in this cohort emphasizes the importance of recognition, diagnostic workup, and interdisciplinary consideration of the genetic implications to patient families. While this aspect raises intriguing questions regarding whether RCCs that are FH-deficient might occur outside of the hereditary setting through somatic FH mutation, epigenetic mechanisms, or otherwise, resolution of this question will require greater experience with these tumors, even beyond the morphologic spectrum of TC-PD. We also characterized an infrequent but real subset of tumors with TC-PD morphology that seem unrelated to FH-deficiency and tend to arise in somewhat older individuals.
On the basis of preliminary observations on a subset of the present cohort (and experience with RCC cases even without the TC-PD pattern 18 ) we proposed at the 2015 USCAP meeting 21 use of the provisional diagnostic term, FH-deficient RCC, for tumors with suggestive morphology and FH À 2SC+ immunophenotype but where HLRCC stigmata/history cannot be reliably ascertained and genetic testing is urged. We believe that this diagnostic term, when rigorously applied based on both distinctive histopathologic features and increasingly reliable IHC, allows triage for further workup or establishment of HLRCC by genetic testing. It is also adaptable to emerging technologies such as NGS-based tumor mutation profiling, which we suspect will also be used to identify FH-deficient RCCs with some frequency going forward. It also allows designation of cases that might represent apparently sporadic forms, and standardizes analogous terminology between FH-deficient RCC and SDH-deficient RCC, 46,47 2 settings where a constellation of characteristic morphology and immunophenotype are used to establish diagnosis of tumors strongly associated with hereditary disease, and where referral for genetic counseling is urged. Finally, prospective studies of cases recognized as FH-deficient RCC with consent for comprehensive comparative constitutional and tumor molecular profiling and family genetic counseling would enable ascertainment of the relative prevalence of apparent germline versus somatic mutations, addressing one of the principal outstanding questions for this interesting group of tumors.
